Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 2 diabetes mellitus in multiple clinical settings. Sold as Actos. Every FDA application for this active ingredient: 1 branded and 16 generic.
As of Nov 15, 2026, FDA lists 17 applications for Pioglitazone Hydrochloride (sold as Actos), first approved Jul 15, 1999, with 5 new uses approved and 0 published complete response letters.
First approved: Jul 15, 1999
Applications: 17
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $46.2M
First approved in the EU: Oct 11, 2000
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
ActosDrugs with a new indication and a new dosage for the treatment of Type 2 diabetes mellitus in patients who have not benefitted sufficiently from taking… · Takeda Pharmaceutical Company Limited · Mar 24, 2009
ActosDrugs with a new additional indication for the treatment of Type 2 diabetes mellitus (for use only in patients in whom treatment with biguanides in… · Takeda Pharmaceutical Company Limited · Dec 22, 2008
Clinical Trials
49 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Accord Hlthcare
Zydus Pharms USA Inc